FGF21 variants
AssigneeSanofi
InventorsMark Sommerfeld, Thomas Langer, Oliver Boscheinen, Matthias Dreyer, Werner Dittrich, Paul Habermann
Life of this patent
Estimating the term…
Abstract
The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.
Claims6
A variant of human fibroblast growth factor 21 (FGF21) comprising or consisting of the amino acid sequence of SEQ ID NO:
- 46 or 215.
A variant of human fibroblast growth factor 21 (FGF21), consisting of an amino acid sequence of SEQ ID NO:
- 215.
Dependencies are inferred from the claim text.